Mirum Pharmaceuticals
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMAR...
Latest News
5 days ago · zacks.com
MIRM's Brelovitug Scores Second Phase III Win, Nears BLA Filing in HDVMirum's brelovitug marks a second phase III win in chronic HDV, bringing the company closer to a planned 2027 BLA filing with the FDA.
6 days ago · reuters.com
Mirum's liver infection drug lowers virus levels in second late-stage studyMirum's liver infection drug lowers virus levels in second late-stage study
6 days ago · businesswire.com
Mirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLDFOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLD.
13 days ago · seekingalpha.com
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2026 Earnings Call TranscriptMirum Pharmaceuticals, Inc. ( MIRM ) Q3 2026 Earnings Call November 3, 2026 4:30 PM EST Company Participants Andrew McKibben - Senior Vice President, Strategic Finance & Investor Relations Christopher Peetz - CEO & Director Peter Radovich - COO & President Rob Myers - Chief Medical Officer Eric Bjerkholt - Chief Financial Officer Conference Call Participants Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Luke Herrmann - Robert W. Baird & Co. Incorporated, Research Division Yesha Patel - Evercore ISI Institutional Equities, Research Division Kalpit Patel - Wolfe Research, LLC Ryan Deschner - Raymond James & Associates, Inc., Research Division James Condulis - Stifel, Nicolaus & Company, Incorporated, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Yigal Nochomovitz - Citigroup Inc., Research Division Michael Ulz - Morgan Stanley, Research Division Lisa Walter - RBC Capital Markets, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division Charles Wallace - H.C.
13 days ago · marketbeat.com
Mirum Pharmaceuticals Q3 Earnings Call HighlightsMirum Pharmaceuticals NASDAQ: MIRM reported third-quarter net product sales of $186 million and raised its full-year 2026 net product sales guidance to $715 million to $720 million, citing continued growth of LIVMARLI and its bile acid medicines as well as progress across its late-stage pipeline.
13 days ago · zacks.com
Here's What Key Metrics Tell Us About Mirum Pharmaceuticals (MIRM) Q3 EarningsWhile the top- and bottom-line numbers for Mirum Pharmaceuticals (MIRM) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
13 days ago · zacks.com
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue EstimatesMirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.87 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to earnings of $0.05 per share a year ago.
15 days ago · businesswire.com
Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio with New Data at AASLD's The Liver Meeting® 2026FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio with New Data at AASLD's The Liver Meeting® 2026.
21 days ago · zacks.com
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseMirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
1 month ago · zacks.com
Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver DiseasesMIRM's Livmarli meets the phase III EXPAND study goal, improving cholestatic pruritus and reducing serum bile acids, with an FDA filing planned for 2027.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove MIRM